Cardiology

M.A. Pfeffer, E. Braun-wald, L.A. Moye, L. Basta, E.J. Brown, Jr., T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker, M. Klein, G.A. Lamas, M. Packer, J. Rouleau, J.L. Rouleau, J. Rutherford, J.H. Wertheimer, C.M. Hawkins, for the SAVE investigators, "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction," New England Journal of Medicine, 327:669- 77, 199

The Scientist Staff
May 1, 1994

M.A. Pfeffer, E. Braun-wald, L.A. Moye, L. Basta, E.J. Brown, Jr., T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker, M. Klein, G.A. Lamas, M. Packer, J. Rouleau, J.L. Rouleau, J. Rutherford, J.H. Wertheimer, C.M. Hawkins, for the SAVE investigators, "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction," New England Journal of Medicine, 327:669- 77, 1992.

Marc A. Pfeffer (Harvard Medical School, Boston): "The Survival and Ventricular Enlargement (SAVE) study demonstrated that long- term administration of the angiotensin-converting enzyme (ACE) inhibitor captopril to survivors of myocardial infarction (MI) with ventricular dysfunction prolonged survival. This effect was attributable to reductions both in cardiovascular deaths and in the incidence of heart failure and recurrent MI.

"Rationale for this novel use of ACE inhibitor therapy came from Janice M. Pfeffer's animal studies showing that this treatment attenuated the progressive left ventricular enlargement and...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?